Schedule 13D ownership disclosure

Rapport Therapeutics Inc

Security class unavailable · CUSIP: 75383L102

Event date: 2024-06-10

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,863,327
Percent of class
5.3000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-24-071732
Form type
SC 13D
Filer
Rapport Therapeutics, Inc.
CIK
CIK 2012593
Filed
Jun 14, 2024
Reporting period
Jun 10, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub